Abstract
Purpose
To assess the results of I-125 episcleral brachytherapy (EB) in uveal melanoma: tumour control, visual acuity (VA), eye preservation and survival.
Patients
Prospective and consecutive study of patients with a diagnosis of uveal melanoma at the Ocular Oncology Unit in the Valladolid University Teaching Hospital treated with EB between September 1997 and June 2008. Ocular examination and extraocular and systemic extension data were registered in a database at the time of the diagnosis and during the follow-up.
Results
Among a total of 310 patients diagnosed between September 1997 and June 2008, 136 were treated with EB (mean age, 58.3). Mean follow-up was 55.3 months. As for tumour type, 66.9% were nodular and 39% mushroom shaped. With respect to size, 80.9% were medium, 7.4% small and 11.8% large. After 4.6 years of follow-up, tumours were controlled in 97.1%, with a 55.1% reduction in mean height; only 2.9% of patients showed recurrence. VA was maintained in 16.2% of patients and 17.6% showed an increase; 33% had retinopathy and 14.6% optic neuropathy. Only 5.1% of patients underwent enucleation due to complications and there has been 1 melanoma-related death to date.
Conclusions
I-125 EB is effective in tumour control, allowing preservation of the eye and useful visual function for the majority of patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Singh A, Topham A (2003) Incidence of uveal melanoma in the United States: 1973–1997. Ophthalmology 110:956–961
Diener-West M, Earle JD, Fine SL et al; Collaborative Ocular Melanoma Study Group (2001) The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report No. 18. Arch Ophthalmol 119:969–982
Augsburger JJ, Schneider S, Freyre J, Brady LW (1999) Survival following enucleation versus plaque radiotherapy in statistically matched subgroups of patients with choroidal melanomas: results in patients treated between 1980 and 1987. Graefes Arch Clin Exp Ophthalmol 237:558–567
Bell JB, Wilson MD (2004) Choroidal melanoma: natural history and management options. Cancer Control 11: 296–303
COMS (1998) The Collaborative Ocular Melanoma Study (COMS) randomized trial of preenucleation radiation of large choroidal melanoma II: initial mortality findings. COMS Report No. 10. Am J Ophthalmol 125:779–796
Finger PT (1997) Radiation therapy for choroidal melanoma. Surv Ophthalmol 42:215–232
Wilson MW, Hungerford JL (1999) Comparison of episcleral plaque and proton beam radiation therapy for the treatment of choroidal melanoma. Ophthalmology 106:1579–1587
Nag S, Quivey JM, Earle JD et al; American Brachytherapy Society (2003) The American Brachytherapy Society recommendations for brachytherapy of uveal melanomas. Int J Radiat Oncol Biol Phys 56:544–555
Finger PT (1997) Radiation therapy for choroidal melanoma. Surv Ophthalmol 42:215–232. Review
Saornil MA, Fisher MR, Campbell RJ et al (1997) Histopathologic study of eyes after iodine I 125 episcleral plaque irradiation for uveal melanoma. Arch Ophthalmol 115:1395–1400
Damato B (2004) Developments in the management of uveal melanoma. Clin Experiment Ophthalmol 32:639–647. Review
Margo CE (2004) The collaborative ocular melanoma study: an overview. Cancer Control 11:304–309
Bell DJ, Wilson MW (2004) Choroidal melanoma: natural history and management options. Cancer Control 11:296–303
Augsburger JJ, Correa ZM, Freire J, Brady LW (1998) Long-term survival in choroidal and ciliary body melanoma after enucleation versus plaque radiation therapy. Ophthalmology 105:1670–1678
Shields CL, Shields JA, Cater J et al (2000) Plaque radiotherapy for uveal melanoma: longterm visual outcome in 1106 consecutive patients. Arch Ophthalmol 118:1219–1228
Sobin LH, Wittekind Ch (2002) UICC: TNM classification of malignant tumours, 6th edn. Wiley, New York
Caminal Mitjana JM, Quintana Casany M, Pera Fabregas J et al (2002) Results of Iodine-125 radiotherapy in the treatment of uveal melanoma. Arch Soc Esp Oftalmol 77:29–38
COMS (2002) The Collaborative Ocular Melanoma Study (COMS) randomized trial of iodine 125 brachytherapy for choroidal melanoma IV: local treatment failure and enucleation in the first 5 years after brachytherapy. COMS Report No. 19. Ophthalmology 109:2197–2206
Valcarcel F, Valverde S, Cardenes H et al (1994) Episcleral iridium-192 wire therapy for choroidal melanomas. Int J Radiat Oncol Biol Phys 30:1091–1097
Damato B, Patel I, Campbell IR et al (2005) Related articles, local tumor control after 106Ru brachytherapy of choroidal melanoma. Int J Radiat Oncol Biol Phys 63:385–391
Correa R, Pera J, Gomez J et al (2009) 125 I plaque brachytherapy in the treatment of choroidal melanoma: a single institution experience in Spain. Brachytherapy 8:290–296
COMS (2001) The Collaborative Ocular Melanoma Study (COMS) randomized trial of iodine 125 brachytherapy for medium choroidal melanoma I: visual acuity after 3 years. COMS Report No. 16. Ophthalmology 108:348–366
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
García-Álvarez, C., Saornil, M.A., López-Lara, F. et al. Episcleral brachytherapy for uveal melanoma: analysis of 136 cases. Clin Transl Oncol 14, 350–355 (2012). https://doi.org/10.1007/s12094-012-0807-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12094-012-0807-1